Literature DB >> 21349923

Seasonal variation in blood drug concentrations and a potential relationship to vitamin D.

Jonatan D Lindh1, Marine L Andersson, Erik Eliasson, Linda Björkhem-Bergman.   

Abstract

The most important enzyme in hepatic drug metabolism is cytochrome P450 3A4. Published in vitro data indicate that vitamin D may up-regulate the expression of the CYP3A4 gene. Individual vitamin D levels are highly dependent on sunlight exposure and show great seasonal variability in northern countries. The aim of the present study was to investigate whether plasma concentrations of CYP3A4 drug substrates exhibit seasonal changes compatible with a stimulatory effect of vitamin D on drug metabolism. Three immunosuppressants (tacrolimus, sirolimus, and cyclosporine) were analyzed, because these CYP3A4 drug substrates are subject to long-term use and repeated concentration determinations. In addition, mycophenolic acid was included in the analysis as a control drug independent of CYP3A4 metabolism. Concentration-to-dose ratios were extracted from the Karolinska Therapeutic Drug Monitoring database and compared between the 3-month periods of lowest and highest vitamin D levels. Sirolimus and tacrolimus levels showed seasonal variability that was highly consistent with changes in vitamin D; for example, significantly lower drug concentrations in July to September than in January to March. As expected, no significant difference was evident for mycophenolic acid, but this result was also the case with cyclosporine, possibly due to cross-reactivity of CYP3A4-mediated metabolites with the immunoassay used for quantification. In conclusion, there is cyclic variation in blood levels of important immunosuppressants throughout the year that correlates with UV light-dependent changes in vitamin D levels. Even though a causal relationship remains to be established, it is suggested that individual differences in vitamin D may contribute to variability in drug metabolism and disposition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21349923     DOI: 10.1124/dmd.111.038125

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  17 in total

Review 1.  [All-rounder vitamin D?]

Authors:  S Unholzer; A Rothmund; E Haen
Journal:  Nervenarzt       Date:  2017-05       Impact factor: 1.214

2.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

3.  Peroxisome Proliferator-Activated Receptor α Activation Suppresses Cytochrome P450 Induction Potential in Mice Treated with Gemfibrozil.

Authors:  Cunzhong Shi; Luo Min; Julin Yang; Manyun Dai; Danjun Song; Huiying Hua; Gangming Xu; Frank J Gonzalez; Aiming Liu
Journal:  Basic Clin Pharmacol Toxicol       Date:  2017-05-10       Impact factor: 4.080

4.  Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation.

Authors:  Ranjit K Thirumaran; Jatinder K Lamba; Richard B Kim; Brad L Urquhart; Jamie C Gregor; Nilesh Chande; Yiping Fan; An Qi; Cheng Cheng; Kenneth E Thummel; Stephen D Hall; Erin G Schuetz
Journal:  Biochem Pharmacol       Date:  2012-03-30       Impact factor: 5.858

Review 5.  CYP3A4 is a crosslink between vitamin D and calcineurin inhibitors in solid organ transplant recipients: implications for bone health.

Authors:  A Prytuła; K Cransberg; A Raes
Journal:  Pharmacogenomics J       Date:  2017-04-18       Impact factor: 3.550

Review 6.  Vitamin paradox in obesity: Deficiency or excess?

Authors:  Shi-Sheng Zhou; Da Li; Na-Na Chen; Yiming Zhou
Journal:  World J Diabetes       Date:  2015-08-25

Review 7.  Interplay between vitamin D and the drug metabolizing enzyme CYP3A4.

Authors:  Zhican Wang; Erin G Schuetz; Yang Xu; Kenneth E Thummel
Journal:  J Steroid Biochem Mol Biol       Date:  2012-09-15       Impact factor: 4.292

Review 8.  Drug-vitamin D interactions: a systematic review of the literature.

Authors:  Kim Robien; Sarah J Oppeneer; Julia A Kelly; Jill M Hamilton-Reeves
Journal:  Nutr Clin Pract       Date:  2013-01-10       Impact factor: 3.080

Review 9.  Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice?

Authors:  Agnieszka Prytuła; Karlien Cransberg; Ann Raes
Journal:  Pediatr Nephrol       Date:  2018-07-30       Impact factor: 3.714

10.  Vitamin D3 supplementation in patients with frequent respiratory tract infections: a randomised and double-blind intervention study.

Authors:  Peter Bergman; Anna-Carin Norlin; Susanne Hansen; Rokeya Sultana Rekha; Birgitta Agerberth; Linda Björkhem-Bergman; Lena Ekström; Jonatan D Lindh; Jan Andersson
Journal:  BMJ Open       Date:  2012-12-13       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.